Orgovyx is owned by Myovant Sciences.
Orgovyx contains Relugolix.
Orgovyx has a total of 6 drug patents out of which 0 drug patents have expired.
Orgovyx was authorised for market use on 18 December, 2020.
Orgovyx is available in tablet;oral dosage forms.
Orgovyx can be used as treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent, treatment of adult patients with advanced prostate cancer.
Drug patent challenges can be filed against Orgovyx from December, 2024.
The generics of Orgovyx are possible to be released after 29 September, 2037.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8058280 | MYOVANT SCIENCES | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
Jan, 2024
(11 months from now) | |
US7300935 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Jan, 2024
(11 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8735401 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Feb, 2024
(1 year, 4 days from now) | |
US10350170 | MYOVANT SCIENCES | Solid preparation |
Feb, 2036
(13 years from now) | |
US10449191 | MYOVANT SCIENCES | Treatment of prostate cancer |
Sep, 2037
(14 years from now) | |
US10786501 | MYOVANT SCIENCES | Treatment of prostate cancer |
Sep, 2037
(14 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 18, 2025 |
Drugs and Companies using RELUGOLIX ingredient
NCE-1 date: December, 2024
Market Authorisation Date: 18 December, 2020
Treatment: Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent; Treatment of adult patients with advanced prostate cancer
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic